Literature DB >> 6921216

A new screening test for C3 nephritis factor based on a stable cell bound convertase on sheep erythrocytes.

U Rother.   

Abstract

C3 nephritis factor (C3nef) activity was measured by the incubation of sheep erythrocytes with a mixture of normal human serum and patient's serum in EGTA followed by lysis of the washed cells with rat C in EDTA. The C convertase activity on the cells was dependent on the dose of patient's serum. Activation of human C3-C9 by the washed cells was shown by lysis of susceptible target cells (chicken erythrocytes). The test is specific for C3nef.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6921216     DOI: 10.1016/0022-1759(82)90386-6

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  22 in total

Review 1.  Modern complement analysis.

Authors:  Michael Kirschfink; Tom E Mollnes
Journal:  Clin Diagn Lab Immunol       Date:  2003-11

2.  Requirements for the production of high-titre C3 nephritic factor (NEF) antibody in vitro.

Authors:  M A Marín; G Fontán; M López-Trascasa
Journal:  Immunology       Date:  1992-06       Impact factor: 7.397

3.  Eculizumab in Pediatric Dense Deposit Disease.

Authors:  Michiel J S Oosterveld; Mark R Garrelfs; Bernd Hoppe; Sandrine Florquin; Joris J T H Roelofs; L P van den Heuvel; Kerstin Amann; Jean-Claude Davin; Antonia H M Bouts; Pietrik J Schriemer; Jaap W Groothoff
Journal:  Clin J Am Soc Nephrol       Date:  2015-08-27       Impact factor: 8.237

4.  A novel method for direct measurement of complement convertases activity in human serum.

Authors:  A M Blom; E B Volokhina; V Fransson; P Strömberg; L Berghard; M Viktorelius; T E Mollnes; M López-Trascasa; L P van den Heuvel; T H Goodship; K J Marchbank; M Okroj
Journal:  Clin Exp Immunol       Date:  2014-10       Impact factor: 4.330

5.  Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation.

Authors:  Rubén Martínez-Barricarte; Meike Heurich; Francisco Valdes-Cañedo; Eduardo Vazquez-Martul; Eva Torreira; Tamara Montes; Agustín Tortajada; Sheila Pinto; Margarita Lopez-Trascasa; B Paul Morgan; Oscar Llorca; Claire L Harris; Santiago Rodríguez de Córdoba
Journal:  J Clin Invest       Date:  2010-09-13       Impact factor: 14.808

6.  Monitoring of complement activation biomarkers and eculizumab in complement-mediated renal disorders.

Authors:  C Wehling; O Amon; M Bommer; B Hoppe; K Kentouche; G Schalk; R Weimer; M Wiesener; B Hohenstein; B Tönshoff; R Büscher; H Fehrenbach; Ö-N Gök; M Kirschfink
Journal:  Clin Exp Immunol       Date:  2016-11-25       Impact factor: 4.330

7.  Successful therapy of C3Nef-positive C3 glomerulopathy with plasma therapy and immunosuppression.

Authors:  Karsten Häffner; Stefan Michelfelder; Martin Pohl
Journal:  Pediatr Nephrol       Date:  2015-05-19       Impact factor: 3.714

8.  Dense deposit disease in an adolescent male mimicking acute post-streptococcal glomerulonephritis.

Authors:  E Siomou; G Liapis; A Zisi; D Csuka; Z Prohászka
Journal:  Hippokratia       Date:  2020 Oct-Dec       Impact factor: 0.471

9.  Nephritic factor and recurrence in the renal transplant of membranoproliferative glomerulonephritis type II.

Authors:  Clark D West; John J Bissler
Journal:  Pediatr Nephrol       Date:  2008-07-02       Impact factor: 3.714

10.  Factor D Inhibition Blocks Complement Activation Induced by Mutant Factor B Associated With Atypical Hemolytic Uremic Syndrome and Membranoproliferative Glomerulonephritis.

Authors:  Sigridur Sunna Aradottir; Ann-Charlotte Kristoffersson; Lubka T Roumenina; Anna Bjerre; Pavlos Kashioulis; Runolfur Palsson; Diana Karpman
Journal:  Front Immunol       Date:  2021-06-10       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.